On Tuesday, Shares of Alibaba Group Holding Ltd (NYSE:BABA), subtract -0.21% and shut at $93.21 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $93.16 and $94.42. Alibaba Cloud, the cloud computing arm of Alibaba Group, recently declared the opening of four new data centers by the end of 2016 in the Middle East (Dubai), Europe, Australia and Japan. As a major milestone of Alibaba Cloud’s global expansion, the new centers will boost its data center network to 14 locations, covering key economic centers around the world. The data center in the Middle East, located in Dubai, United Arab Emirates, begind initial operations recently.
Alibaba Cloud’s expansion will provide customers worldwide with improved latency and greater access to its diverse offerings, counting data storage and analytics services, enterprise-level middleware, and cloud security services. Strengthening Alibaba Cloud’s position as a major global cloud provider, the new data centers will support Alibaba Cloud’s growing client base beyond the current 2.3 million.
Shares of Bristol-Myers Squibb Co (NYSE:BMY), subtract -0.32% and shut at $56.55 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $56.26 and $56.90. The association’s commercial center capitalization is $94.46 Billion with the general uncommon loads of 1.67 billion. Bristol-Myers Squibb Company (BMY) recently declared the European Commission approved Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin. Opdivo is now the first and only PD-1 inhibitor approved for a hematologic malignancy in the European Union (EU). This approval allows for the expanded marketing of Opdivo in relapsed or refractory cHL in all 28 Member States of the EU.
The approval is based on an integrated analysis of data from the Phase 2 CheckMate -205 and the Phase 1 CheckMate -039 trials, evaluating patients with relapsed or refractory cHL after ASCT and treatment with brentuximab vedotin. In the subset of patients in the efficacy population (n=95), the primary endpoint of objective response rate (ORR) as assessed by an independent radiologic review committee was 66% (95% CI: 56-76; 63/95 patients). The percentage of patients with a complete response was 6% (95% CI: 2-13; 6/95 patients), and the percentage of patients with a partial response was 60% (95% CI: 49-70; 57/95 patients). At 12 months, the progression-free survival rate was 57% (95% CI: 45-68). Opdivo is associated with warnings and precautions counting immune-related: pneumonitis, colitis, hepatitis, nephritis and renal dysfunction, endocrinopathies, rash, and other adverse reactions; infusion reactions, and complications of allogeneic hematopoietic stem cell transplantation (HSCT) in cHL after Opdivo.